GeNeuro: financial information for the second quarter 2023

Geneva, Switzerland, July 25, 2023 – 6.00 pm CEST – GeNeuro (Euronext Paris: CH0308403085 – GNRO), a biopharmaceutical company developing treatments for neurodegenerative and autoimmune diseases, such as multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS) and the severe neuropsychiatric consequences of COVID-19 (post-COVID or Long-COVID), today reported on its 2023 second quarter cash position. https://geneuro.ch/data/news/GeNeuro-PR-Q2-2023-EN.pdf